Navigation Links
Amylin Pharmaceuticals to Webcast Third Quarter Results

SAN DIEGO, Oct. 15 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will Webcast its Quarterly Update Conference Call for the third quarter of 2008 on Tuesday, October 21, 2008 at 5:00 p.m. ET/2:00 p.m. PT. Daniel M. Bradbury, Amylin's President and Chief Executive Officer, will lead the call. On the same date post-market, Amylin will release financial results for the third quarter of 2008.

The call will be Webcast live through Amylin's corporate Web site and a recording will be made available following the close of the call. To access the Webcast, please log on to approximately fifteen minutes prior to the call to register, download and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (888) 536-6007 (U.S./Canada) or (706) 758-4632 (international), Conference ID# 68128288. A replay of the call will also be available by phone beginning approximately two hours after the close of the call and can be accessed at (800) 642-1687 (U.S./Canada) or (706) 645-9291 (international), Conference ID# 68128288.

About Amylin Pharmaceuticals, Inc.

Amylin Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is located in San Diego, California with over 2,000 employees nationwide. Further information on Amylin Pharmaceuticals is available at

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Amylin Pharmaceuticals to Present at Thomas Weisel Healthcare, BioCentury NewsMakers, and Morgan Stanley Global Healthcare Conferences
2. Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA
3. Amylin and Lilly Set Date and Time for Conference Call
4. Amylin Pharmaceuticals to Webcast Second Quarter Results
5. Amylin Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference
6. Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008
7. Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders
8. Amylin Pharmaceuticals to Present at FBR Capital Markets Investor Conference
9. Amylin Pharmaceuticals to Present at Baird Growth Stock Conference
10. Amylin Pharmaceuticals to Present at Bank of America Healthcare Conference
11. Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
(Date:11/30/2015)... - BioAmber Inc. (NYSE: BIOA ), a leader in renewable ... Act on Climate Pledge, alongside more than 140 companies from ... Administration to demonstrate an ongoing commitment to climate action and ... Paris climate negotiations. ... . --> BioAmber uses biotechnology to convert ...
(Date:11/30/2015)... , Nov. 30, 2015 Harvard ... ), a biotechnology company developing bioengineered organ implants ... written notification from The NASDAQ Stock Market that ... price requirements. The letter noted that as a ... common stock having exceeded $1.00 per share for ...
(Date:11/30/2015)... GA (PRWEB) , ... November 30, 2015 , ... ... a new globally touring exhibition Jurassic World: The Exhibition, opening in March 2016 ... will embark on a worldwide tour including several North American tour dates. The ...
(Date:11/30/2015)... 30, 2015 TapImmune, Inc. ... of innovative peptide and gene-based immunotherapeutics and vaccines for ... it will be presenting at the 8 th ... at 2.30 PM PT. Dr. John N. Bonfiglio ... be giving the presentation and will join TapImmune management ...
Breaking Biology Technology:
(Date:11/16/2015)... Nov 16, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced expansion of its TDDI product ... touch controller and display driver integration (TDDI) solutions ... These new TDDI products add to the previously-announced ... TD4302 (WQHD resolution), and TD4322 (FHD resolution) solutions. ...
(Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
(Date:11/2/2015)...  SRI International has been awarded a contract of ... to the National Cancer Institute (NCI) PREVENT Cancer Program ... modern testing and support facilities, and analytical instrumentation to ... studies to evaluate potential cancer prevention drugs. ... Drug Development Program is an NCI-supported pipeline to bring ...
Breaking Biology News(10 mins):